Relief Therapeutics Holding SA

Relief Therapeutics Holding SA is a Swiss commercial-stage biopharmaceutical company dedicated to developing and bringing to market innovative, patent-protected therapies for rare and ultra-rare diseases. Its portfolio targets specialized areas, notably metabolic, dermatological, and pulmonary conditions. Signature products include SETOFILM/ONDISSOLVE, for managing nausea linked to cancer therapies, and OLPRUVA, used in treating urea cycle disorders and maple syrup urine disease. The company is also advancing several pipeline candidates, such as RLF-100 for acute respiratory distress syndrome and RLF-TD011 for wound care. Relief Therapeutics operates globally, serving Europe, North America, and other international markets, and plays a crucial role in addressing unmet medical needs in niche patient populations. With a foundation in science and innovation, the company exemplifies the biotechnology sector’s focus on orphan drugs and the development of solutions for conditions lacking adequate treatments.